新型 Dex-bHb 作为氧载体的体外和体内研究。
In vitro and in vivo investigation of the novel Dex-bHb as oxygen carriers.
机构信息
a Institute of Health Service and Transfusion Medicine, Academy of Military Medical Sciences , Beijing , China;
b State Key Laboratory of Biochemical Engineering , Institute of Process Engineering, Chinese Academy of Sciences , Beijing , China.
出版信息
Artif Cells Nanomed Biotechnol. 2018;46(sup3):S133-S137. doi: 10.1080/21691401.2018.1489273. Epub 2019 Jan 8.
The development of hemoglobin-based oxygen carriers (HBOCs) is a persistent and urgent need in biomedicine. As a potential HBOCs, Dextran-hemoglobin (Dex-bHb) has been developed over the past years. The novel Dex-bHb, whose thiol group of Cys-93(β) was reversibly protected, was produced and the characteristics were evaluated in our previous study. Herein, blood compatibility was characterized in terms of the red blood cell aggregation and hemolysis rate in vitro, and Dex-bHb showed no obvious effects. After intravenous administration of Dex-bHb to golden Syrian hamsters with hemorrhages shock, it showed mean arterial pressure recovery, blood flow increase and the organ protection from serious hemorrhage injury. Consequently, Dex-bHb is hopeful to be a safe and available blood substitute.
血红蛋白类氧载体（HBOCs）的开发在生物医药领域是一个持续且紧迫的需求。作为一种潜在的 HBOCs，葡聚糖-血红蛋白（Dex-bHb）在过去几年中得到了发展。我们之前的研究中制备了一种新型的 Dex-bHb，其 Cys-93(β)的巯基基团被可逆地保护。在此，通过体外的红细胞聚集和溶血率来评价其血液相容性，结果表明 Dex-bHb 没有明显的影响。将 Dex-bHb 静脉注射到有出血性休克的金黄叙利亚仓鼠体内后，它能恢复平均动脉压、增加血流量并保护器官免受严重出血损伤。因此，Dex-bHb 有望成为一种安全有效的血液替代品。
Zotero 插件